Pharsight

Application	Filing Date	Opposition Party	Legal Status

EP13737808A	2021-01-08	Galenicum Health S.L.U.	Granted and Under Opposition
EP13737808A	2021-01-07	Teva Pharmaceutical Industries LTD.	Granted and Under Opposition
EP13737808A	2021-01-07	Generics [UK] Limited	Granted and Under Opposition
EP06725149A	2011-05-04	AMYLIN PHARMACEUTICALS, INC.	Opposition rejected

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US8129343	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.
US8536122	March, 2023	PO preliminary response filed	Novo Nordisk A/S	Mylan Pharmaceuticals Inc. et al.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8536122	NOVO	Acylated GLP-1 compounds	Mar, 2026 (2 years from now)
US8129343	NOVO	Acylated GLP-1 compounds	Dec, 2031 (8 years from now)
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9764003	NOVO	Use of long-acting GLP-1 peptides	Jun, 2033 (9 years from now)
US10888605	NOVO	GLP-1 compositions and uses thereof	Aug, 2038 (14 years from now)
US11318191	NOVO	GLP-1 compositions and uses thereof	Feb, 2041 (17 years from now)

Wegovy is owned by Novo.

Wegovy contains Semaglutide.

Wegovy has a total of 5 drug patents out of which 0 drug patents have expired.

Wegovy was authorised for market use on 04 June, 2021.

Wegovy is available in solution;subcutaneous dosage forms.

Wegovy can be used as method for weight management, method for weight management according to a dose escalation schedule.

The generics of Wegovy are possible to be released after 17 February, 2041.

Drug Exclusivity	Drug Exclusivity Expiration
New Product (NP)	Jun 4, 2024
New Patient Population (NPP)	Dec 23, 2025

Market Authorisation Date: 04 June, 2021

Treatment: Method for weight management according to a dose escalation schedule; Method for weight management

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.25 mg/0.5 mL 0.5 mg/0.5 mL 1 mg/0.5 mL 1.7 mg/0.75 mL 2.4 mg/0.75 mL	20 Oct, 2022	1		17 Feb, 2041

WEGOVY family patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic